A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
about
Targeting Src family kinases in anti-cancer therapies: turning promise into triumphMetastasis-associated PRL-3 induces EGFR activation and addiction in cancer cellsPhosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutantsSystematic identification of genomic markers of drug sensitivity in cancer cellsClinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma.Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence.Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis.Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.Tumour suppressor genes in chemotherapeutic drug response.PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological AssessmentsSETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.Comprehensive Characterization of Molecular Differences in Cancer between Male and Female PatientsIncreased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.Determining target engagement in living systemsTargeted therapies in metastatic renal cell carcinoma: overview of the past year.Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
P2860
Q27025646-24CE2785-0DA0-4FBD-B9B6-7BD395F8E1E2Q27852452-D0DCEEE0-A40D-4BB9-BE36-A324B35AB558Q28293851-A7243B9E-5D63-4E3B-AE44-C08E4242166DQ29547695-8239E363-65C9-4F96-8FEB-EC948E8D1083Q33602552-53AAA510-ABDD-4C9D-922A-167CCB0BB816Q33640700-0CDF231B-0CEB-478E-A30B-52603C0B0844Q34155348-797D94AE-1A58-4FA9-86CC-008BC4960605Q34184654-7F985437-C88F-4238-8E04-D2B5FAEBDE14Q34217927-3E59DA23-93BC-4ABD-B821-8D2580040481Q35960176-D457C7DF-CDE3-4AEE-BEF2-3F97574A1902Q36083098-325EC490-E63E-4692-A2F9-4DC034339CD6Q36255955-FC549F28-9535-44D0-B49E-6C8E7D8F8331Q36320349-CBFF7956-4E23-4F6F-85DA-93B47D29C1C1Q36545062-051CBA8B-A1C7-428B-B400-10221BBC3054Q36608758-AFF49CA2-DC6F-45FD-8750-C3064F1BACF8Q36895507-8B7825AA-0830-4BC9-B1D0-03D1D26543EDQ37225442-1B188535-1258-42FE-A212-C746E86B4067Q37367858-2433F5A9-B3DC-4679-B734-3EFE2C3BE89AQ37418248-7884D2EA-D821-47F4-A9B8-1E530357E238Q37732146-69D77C13-695A-41CF-B1AE-81A50DA5E687Q37964565-1F24B35C-AE13-45B5-A155-7281CABF5ED2Q38268873-64482DF8-8117-4F74-B78D-8F95419041E3Q38815335-A576BD6F-B49C-4533-877B-0A8ECAB80355Q50085792-0158659B-4CE8-4677-945E-7AAB4463CD40
P2860
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@en
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@nl
type
label
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@en
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@nl
prefLabel
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@en
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@nl
P2093
P2860
P50
P1476
A HIF-regulated VHL-PTP1B-Src ...... arget in renal cell carcinoma.
@en
P2093
Charles L Sawyers
David Z Qian
Elsa Vanhecke
Gary Thomas
George V Thomas
Holger Moch
James Larkin
Johann De-Bono
Joshi J Alumkal
P2860
P304
P356
10.1126/SCITRANSLMED.3002004
P407
P577
2011-06-01T00:00:00Z